9/16/2019 8:02:47 AM
Seattle Genetics And Astellas: FDA Grants Priority Review For Enfortumab Vedotin BLA
7/16/2019 4:05:52 PM
Seattle Genetics Q2 Loss/share $0.49 Vs. Profit $0.47 Year Ago
7/16/2019 8:19:27 AM
Astellas And Seattle Genetics Announce Submission Of Biologics License Application To FDA For Enfortumab Vedotin
7/16/2019 8:09:39 AM
Seattle Genetics, Astellas Announce Submission Of BLA For Enfortumab Vedotin
6/24/2019 9:02:04 AM
PDL BioPharma Elects Natasha Hernday To Board
6/3/2019 7:35:06 AM
Astellas Pharma, Seattle Genetics Announce Enfortumab Vedotin Produced Tumor Response Rate Of 44%
4/25/2019 4:28:34 PM
Seattle Genetics Q1 Loss/share $0.08 Vs. Loss $0.73 Year Ago
3/29/2019 8:09:42 AM
Seattle Genetics Closes Enrollment In Tisotumab Vedotin Phase 2 Clinical Trial In Recurrent/Metastatic Cervical Cancer
3/28/2019 3:25:21 AM
Seattle Genetics, Astellas Announce Results From Trial Of Enfortumab Vedoti
3/27/2019 8:08:31 AM
Seattle Genetics Highlights Antibody-Drug Conjugate Innovation And Immuno-Oncology Program At AACR Annual Meeting
3/25/2019 7:32:25 AM
William Blair Reiterates Seattle Genetics Inc. (SGEN) At Outperform